

## Structural and Biochemical Perspectives on Post-Translational Modifications of Transcription Factors in Neurodegenerative Disorders: Implications for Disease Progression and Therapeutic Targeting

Patricia González, Viktor Kovács, Luka Marković, Ayse Demir

### Article Information

Received: 10-01-2023

Revised: 02-02-2023

Accepted: 20-02-2023

Published: 15-03-2023

### Keywords

Neurodegenerative disorders

Alzheimer's disease

Parkinson's disease

### ABSTRACT

Neurodegenerative disorders (NDs), including Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), and amyotrophic lateral sclerosis (ALS), are characterized by progressive neuronal loss, often linked to dysregulation of transcription factors (TFs). Post-translational modifications (PTMs) such as phosphorylation, acetylation, ubiquitination, and sumoylation play crucial roles in modulating TF activity, stability, and DNA-binding efficiency. This study provides a structural and biochemical analysis of PTMs in key TFs implicated in NDs, elucidating their role in pathogenesis and potential as therapeutic targets. By integrating proteomics, molecular modeling, and in vitro validation, we highlight specific PTM-driven dysfunctions contributing to disease progression and explore potential intervention strategies.

### INTRODUCTION:

Neurodegenerative disorders (NDs) are complex diseases marked by the gradual loss of neuronal function. Transcription factors (TFs) regulate gene expression critical for neuronal homeostasis, synaptic plasticity, and cellular stress responses. Disruptions in TF function, driven by PTMs, contribute to pathogenic cascades in NDs. Understanding these modifications from a structural and biochemical perspective is essential for developing targeted therapies. This study systematically examines the impact of PTMs on TFs in NDs, integrating computational and experimental approaches.

### Post-Translational Modifications in Neurodegenerative Disorders Phosphorylation and Neurodegeneration




Fig. Phosphorylation and Neurodegeneration

### ©2023 The authors

This is an Open Access article distributed under the terms of the Creative Commons Attribution (CC BY NC), which permits unrestricted use, distribution, and reproduction in any medium, as long as the original authors and source are cited. No permission is required from the authors or the publishers. (<https://creativecommons.org/licenses/by-nc/4.0/>)

Phosphorylation modulates TF activity by altering protein conformation and DNA-binding affinity. Aberrant phosphorylation of TFs such as CREB, FOXO3, and NF- $\kappa$ B has been implicated in neurotoxicity and apoptosis.

### Acetylation and Epigenetic Dysregulation

Histone acetyltransferases (HATs) and histone deacetylases (HDACs) regulate TF acetylation, affecting transcriptional activity. In AD and PD, TF acetylation imbalances contribute to neuroinflammation and synaptic dysfunction.

### Ubiquitination and Proteasomal Degradation

Ubiquitination directs TFs for proteasomal degradation, regulating cellular homeostasis. Dysregulated ubiquitination in HD and ALS disrupts TF-mediated transcriptional networks, exacerbating neuronal loss.

### Sumoylation and Nuclear-Cytoplasmic Shuttling

Sumoylation influences TF subcellular localization and activity. Dysfunctional sumoylation of p53 and SP1 in NDs impairs neuroprotective gene expression.

### Structural Insights into PTM-Induced TF Dysregulation




Fig. PTM-Induced TF Dysregulation

Molecular dynamics simulations and structural modeling reveal conformational shifts in TFs upon PTM alterations. Cryo-EM and X-ray crystallography studies further validate structural perturbations that impact transcriptional regulation.

### Therapeutic Targeting of TF PTMs in Neurodegeneration

Targeting PTM-modifying enzymes, such as kinases, phosphatases, and ubiquitin ligases, presents a viable strategy for restoring TF function. Small-molecule inhibitors and CRISPR-based epigenetic editing offer promising avenues for therapeutic intervention.

### CONCLUSION:

PTMs critically modulate TF function in NDs, influencing disease onset and progression. A structural and biochemical understanding of these modifications paves the way for novel therapeutic strategies aimed at restoring transcriptional integrity in neurodegenerative diseases.

### REFERENCES:

1. Lu, T., Aron, L., Zullo, J., et al. (2014). REST and stress resistance in aging and Alzheimer's disease. *Nature*, 507(7493), 448-454.
2. Saha, R. N., & Pahan, K. (2006). HATs and HDACs in neurodegeneration: a tale of disconcerted acetylation homeostasis. *Cell Death and Differentiation*, 13(4), 539-550.
3. Salminen, A., Kauppinen, A., Kaarniranta, K. (2013). Epigenetic regulation of aging and neurodegeneration. *Ageing Research Reviews*, 12(2), 503-519.
4. Sbodio, J. I., Paul, B. D., & Snyder, S. H. (2017). Transcription factors in neurodegeneration. *Seminars in Cell & Developmental Biology*, 64, 154-161.
5. Caccamo, A., Magri, A., Medina, D. X., et al. (2013). mTOR regulates tau phosphorylation and degradation. *Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease*, 1832(12), 2486-2497.
6. Love, S., Barber, R., & Wilcock, G. K. (1999). Apoptosis and expression of cell cycle proteins in dementia. *American Journal of Pathology*, 154(2), 361-372.
7. De Strooper, B., & Karran, E. (2016). The cellular phase of Alzheimer's disease. *Cell*, 164(4), 603-615.
8. West, M. J., Coleman, P. D., Flood, D. G., & Troncoso, J. C. (1994). Differences in the pattern of hippocampal neuronal loss in normal ageing and Alzheimer's disease. *The Lancet*, 344(8925), 769-772.
9. Venkatesh, S., & Workman, J. L. (2015). Histone exchange, chromatin structure and the regulation of transcription. *Nature Reviews Molecular Cell Biology*, 16(3), 178-189.
10. Pires, G., & Hamacher-Brady, A. (2018). Nuclear role of GAPDH as a regulator of transcription factors in cell death and survival. *Cellular Signalling*, 47, 67-80.
11. Yan, X., Hu, Y., & Wang, B. (2020). Regulation of transcription factor function by PTMs in neurodegenerative diseases. *Neuroscience Letters*, 714, 134611.
12. Nandi, D., Tahiliani, P., Kumar, A., & Chandu, D. (2006). The ubiquitin-proteasome system. *Journal of Biosciences*, 31(1), 137-155.
13. Kim, W. S., & Sidhu, A. (2016). The role of SUMOylation in transcriptional regulation in neurodegenerative diseases. *Neurochemical Research*, 41(3), 483-489.